EVALUATION OF 2ND GENERATION CA-125 ASSAYS

被引:3
作者
COSMI, EV
ATLANTE, G
DONADIO, C
MARIANI, L
BARBATI, A
机构
[1] UNIV ROMA LA SAPIENZA,POLICLIN UMBERTO 1,IST OSTETR & GINECOL 2,I-00161 ROME,ITALY
[2] REGINA ELENA INST CANC RES,DEPT GYNECOL ONCOL,ROME,ITALY
[3] SAN CAMILLO HOSP,OBSTET & GYNECOL UNIT,ROME,ITALY
来源
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY | 1995年 / 58卷 / 01期
关键词
CA-125; SERUM; 2ND GENERATION ASSAY;
D O I
10.1016/0028-2243(94)01974-C
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: This study was performed in order to evaluate and compare the serum CA 125 values obtained using an immunoradiometric (IRMA-II) and an immunoenzymatic (ETI-II) second generation assay, and to establish whether or not the two methods may be used interchangeably. Study design: Serum CA 125 levels were measured in parallel using IRMA-II and ETI-II CA 125 assays (Sorin Biomedical), in 82 women with benign or malignant gynecological diseases. Statistical analysis was performed by linear regression analysis and Wilcoxon's test. Results. Serum CA 125 levels measured using the immunoenzymatic method were lower than those obtained by the immunoradiometric assay. The largest discrepancies between the two methods were found at concentrations of 35-100 U/ml, within which fall cutoff values for the immunoradiometric assay. The cutoff values of 35 or 65 U/ml, frequently used in the original immunoradiometric assay and retained for the immunoradiometric second generation assay, corresponded to 18 and 47 U/ml in the immunoenzymatic second generation assay. Conclusion: The discrepancies in CA 125 results obtained by the two detection methods imply that the cutoff values used in the immunoenzymatic procedure should have a lower reference value in order to eliminate high rates of false negative results. Furthermore, their interchangeable use should be avoided in the monitoring of ovarian cancer and other gynecological diseases.
引用
收藏
页码:73 / 76
页数:4
相关论文
共 12 条
[1]   A RADIOIMMUNOASSAY USING A MONOCLONAL-ANTIBODY TO MONITOR THE COURSE OF EPITHELIAL OVARIAN-CANCER [J].
BAST, RC ;
KLUG, TL ;
STJOHN, E ;
JENISON, E ;
NILOFF, JM ;
LAZARUS, H ;
BERKOWITZ, RS ;
LEAVITT, T ;
GRIFFITHS, CT ;
PARKER, L ;
ZURAWSKI, VR ;
KNAPP, RC .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (15) :883-887
[2]   REACTIVITY OF A MONOCLONAL-ANTIBODY WITH HUMAN OVARIAN-CARCINOMA [J].
BAST, RC ;
FEENEY, M ;
LAZARUS, H ;
NADLER, LM ;
COLVIN, RB ;
KNAPP, RC .
JOURNAL OF CLINICAL INVESTIGATION, 1981, 68 (05) :1331-1337
[3]  
BOERMAN OC, 1990, CLIN CHEM, V36, P888
[4]   LONGITUDINAL-STUDY OF CEA AND CA125 IN OVARIAN-CANCER [J].
BRIOSCHI, PA ;
BISCHOF, P ;
RAPIN, C ;
DEROTEN, M ;
IRION, O ;
KRAUER, F .
GYNECOLOGIC ONCOLOGY, 1985, 21 (01) :1-6
[5]  
JAGER W, 1993, CLIN CHEM, V39, P1556
[6]   TISSUE DISTRIBUTION OF A COELOMIC-EPITHELIUM-RELATED ANTIGEN RECOGNIZED BY THE MONOCLONAL ANTIBODY-OC125 [J].
KABAWAT, SE ;
BAST, RC ;
BHAN, AK ;
WELCH, WR ;
KNAPP, RC ;
COLVIN, RB .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1983, 2 (03) :275-285
[7]  
KENEMANS P, 1993, CLIN CHEM, V39, P2509
[8]  
KLUG TL, 1984, CANCER RES, V44, P1048
[9]   NEW MONOCLONAL-ANTIBODIES IDENTIFY THE GLYCOPROTEIN CARRYING THE CA-125 EPITOPE [J].
OBRIEN, TJ ;
RAYMOND, LM ;
BANNON, GA ;
FORD, DH ;
HARDARDOTTIR, H ;
MILLER, FC ;
QUIRK, JG .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1991, 165 (06) :1857-1864